

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0086
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO			C mplete if Kn wn		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/531,969	
			Filing Date	March 21, 2000	
			First Named Inventor	Jan Geliebter	
			Art Unit	1632	
			Examiner Name	Peter Paras, Jr.	
Sheet	1	of	4	Attorney Docket Number	96700/596

RECEIVED
MAY 24 2002
PATENT CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
PP	1	US- 6,150,338	Nov. 21, 2000	Geliebter, et al.	
	2	US- 5,594,032	Jan. 14, 1997	Gonzalez-Cadavid, et al.	
	3	US- 5,324,651	June 28, 1994	Ono, et al.	
	4	US- 5,214,030	May 25, 1993	Stief	
	5	US- 5,219,748	June 15, 1993	Yoshitaka, et al.	
	6	US- 5,776,734	July 7, 1998	Kaczorowski et al.	
	7	US- 6,156,497	Dec. 5, 2000	Kaleko	
PP	8	US- 6,271,211 B1	Aug. 7, 2001	Christ et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
PP	1	WO 00/10604 ✓	March 2, 2000	Albert Einstein		
I	2	WO 98/33529 ✓	August 6, 1998	Genemedicine, Inc.		
PP	3	WO 98/36055 ✓	August 20, 1998	Albert Einstein		

Examiner Signature	<i>Pete Paras</i>	Date Considered	7/23/02
-----------------------	-------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0951-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED
MAY 24 2002
PATENT CENTER 1800/2900

Substitute for form 1449B/PTO		C m p l e t e if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/531,969		
		Filing Date	March 21, 2000		
		First Named Inventor	Jan Geliebter		
		Group Art Unit	1632		
		Examiner Name	Peter Paras, Jr.		
Sheet	2	of	4	Attorney Docket Number	96700/596


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PJ	1	Christ, G.J., The Control of Corporal Smooth Muscle Tone, the Coordination of Penile Erection, and the Etiology of Erectile Dysfunction: The Devil is in the Details: JSET 23:187-193 (1998).	
	2	Christ, G.J., A New Frontier: Gene Therapy for Erectile Dysfunction: In Erectile Dysfunction: issues in current pharmacotherapy Martin Dunitz Ltd. (London) pp. 209-230 (1998).	
	3	Christ, G.J., The "Syncytial Tissue Triad": A Model for Understanding How Gap Junctions Participate in the Local Control of Penile Erection: World J. Urol. 15:36-44 (1997).	
	4	Christ, G.J., The Penis as a Vascular Organ. The Importance of Corporal Smooth Muscle Tone in the Control of Erection: Urologic Clinics of North America, 22(4):727-745 (1995).	
	5	Christ and Brink, Gap Junctions in Isolated Rat Aorta: Evidence for Contractile Responses that Exhibit a Differential Dependence on Intercellular Communication: Brazilian Journal of Medical and Biological Research 33:423-429 (2000).	
	6	Christ and Melman, The Application of Gene Therapy to the Treatment of Erectile Dysfunction: International Journal of Impotence Research 10:111-112 (1998).	
	7	Christ and Melman, Molecular Studies of Human Corporal Smooth Muscle: Implications for the Understanding, Diagnosis, and Treatment of Erectile Dysfunction: Molecular Urology 1:45-54 (1997).	
	8	Christ, et al., Ion Channels and Gap Junctions: Their Role in Erectile Physiology, Dysfunction, and Future Therapy: Molecular Urology 3:61-73 (1999).	
	9	Christ, et al., Intracorporal Injection of hSlo cDNA in Rats Produces Physiologically Relevant Alterations in Penile Function: Am. J. Physiol. 275:H600-H608 (1998).	
	10	Christ, et al., Integrative Erectile Biology: The Role of Signal Transduction and Cell-to-cell Communication in Coordinating Corporal Smooth Muscle Tone and Penile Erection: International Journal of Impotence Research 9:69-84 (1997).	
	PJ	11	Christ, et al., Characterization of K Currents in Cultured Human Corporal Smooth Muscle Cells: Journal of Andrology, 14(5):319-328 (1993).

Examiner Signature	<i>Pete Paras</i>	Date Considered	7/23/02
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449B/PTO		Completion if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/531,969
		Filing Date	March 21, 2000
		First Named Inventor	Jan Geliebter
		Group Art Unit	1632
		Examiner Name	Peter Paras, Jr.
		Attorney Docket Number	96700/596
Sheet	3	of	4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PJ	12	Christ, et al., The Role of Gap Junctions and Ion Channels in the Modulation of Electrical and Chemical Signals in Human Corpus Cavernosum Smooth Muscle: Int. J. Impotence Res. 5:77-96 (1993).	
	13	Crystal, R.G., Transfer of Genes to Humans: Early Lessons and Obstacles to Success: Science 270:404-410 (1993).	
	14	Deonarain, M.P., Ligand-targeted Receptor-mediated Vectors for Gene Delivery: Exp. Opin. Ther. Patents 8(1):53-69 (1998).	
	15	Eck and Wilson, Gene-based Therapy: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Chap. 5, 77-101 (1995).	
	16	Fan, et al., An Analysis of the Maxi-K+ (Kca) Channel in Cultured Human Corporal Smooth Muscle Cells: The Journal of Urology 153:818-825 (1995).	
	17	Gopalakrishnan, et al., Pharmacology of Human Sulphonylurea Receptor SUR1 and Inward Rectifier K+ Channel Kir6.2 Combination Expressed in HEK-293 Cells: British Journal of Pharmacology 129:1323-1332 (2000).	
	18	Lee, et al., Characterization of ATP-Sensitive Potassium Channels in Human Corporal Smooth Muscle Cells: Int. J. Impotence Res. 11:179-188 (1999).	
	19	Lee, et al., Prostaglandin E1 Activates the Large-Conductance Kca Channel in Human Corporal Smooth Muscle Cells: Int. J. Impotence Res. 11:189-199 (1999).	
	20	Lerner, et al., A Review of Erectile Dysfunction: New Insights and More Questions: The Journal of Urology 149:1246-1255 (1993).	
	21	McCobb, et al., A Human Calcium-activated Potassium Channel Gene Expressed in Vascular Smooth Muscle: Am. J. Physiol. H767-H777 (1995).	
	PJ	22	Melman and Christ, The Hemodynamics of Erection and the Pharmacotherapy of Erectile Dysfunction. In Cardiovascular Pharmacotherapeutics, J. Hefta and P. Touboul, eds. Part/4 Special Topics, Chap. 56:1221-1229 (1997).


Examiner Signature	<i>Pete Paras</i>	Date Considered	7/23/02
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED
MAY 24 2002
TECH CENTER 1600 2800

Substitute for form 1449B/PTO		Compleat if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/531,969
		Filing Date	March 21, 2000
		First Named Inventor	Jan Geliebter
		Group Art Unit	1632
		Examiner Name	Peter Paras, Jr.
Sheet	4	of	4
		Attorney Docket Number	96700/596

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PP	23	Miller and Vile, Targeted Vectors for Gene Therapy: FASEB Journal 9:190-199 (1995).	
	24	Nabel, et al., Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall: Science 249:1285-1288 (1990).	
	25	Rehman, et al., Experimental Hyperprolactinemia in a Rat Model: Alteration in Centrally Mediated Neuroerectile Mechanisms: Int. J. Imp. Res. 12:23-32 (2000).	
	26	Rehman, et al., Diminished Neurogenic but not Pharmacological Erections in the 2- to 3-month Experimentally Diabetic F-344 Rat: Am. J. Physiol., 272:H1960-H1971 (1997).	
	27	Serels, et al., Molecular Studies of Human Connexin 43 (Cx43) Expression in Isolated Corporal Tissue Strips and Cultured Corporal Smooth Muscle Cells: Int. J. Imp. Res. 10:135-143 (1998).	
	28	Verma and Somia., Gene Therapy - Promises, Problems and Prospects: Nature 389:239-242 (1997).	
	29	Wang, et al., Comparative Studies of the Maxi-K (Kca) Channel in Freshly Isolated Myocytes of Human and Rat Corpora: Int. J. Imp. Res. 12:9-18 (2000).	
	30	Wegner, et al., Nitric Oxide Donor, Linsidomine Chlorhydrate (SIN-1), in the Diagnosis and Treatment of Erectile Dysfunction: Critical Appraisal and Review of the Literature: Int. Urology and Nephrology 27(5):621-628 (1995).	
	31	Gelber et al., Cross-desensitization to furosemide and salbutamol in isolated neonatal guinea pig airways. Biol. Neonate 76:98-105 (1999).	
	PP	32	Anderson, Human Gene Therapy: Nature, 392:25-30 (1998).

Examiner Signature	<i>Pete Paras</i>	Date Considered	7/23/02
-----------------------	-------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.